Manic episode associated with Varenicline treatment in a patient with a history of depression

Depresyon öyküsü olan bir hastada Vareniklin tedavisi ile ilişkili manik nöbet

Pınar Kızılay Çankaya1, Evrim Özkorumak Karagüzel2, Ahmet Tiryaki3
1M. D., Ankara Training and Research Hospital, Psychiatry Clinic, Ankara, Turkey https://orcid.org/0000-0001-9683-6000
2Prof. Karadeniz Technical University School of Medicine, Department of Psychiatry, Trabzon. Turkey https://orcid.org/0000-0002-0734-5437
3Prof., İstanbul Aydın University School of Medicine, Department of Psychiatry, İstanbul https://orcid.org/0000-0001-8923-6869

SUMMARY

Varenicline is an alpha 4 beta 2 nicotinic receptor partial agonist with dopaminergic effects. It is an effective and widely used agent approved for smoking cessation. Depressive mood, sleep disorder, suicide, agitation, aggression, psychotic and manic symptoms have been reported during the use of varenicline. We report the case of a 48-year-old woman with a history of major depression who was admitted to the hospital with the diagnosis of mania with psychotic features at the end of the 12-week varenicline treatment. She was admitted to the psychiatry clinic for mystic grandiose and reference delusions, auditory and visual hallucinations, irritability, insomnia, and rapid speech. She was in antidepressant treatment with 100 mg/day sertraline for 2 years and was euthymic for the last 18 months. In her history, she never had symptoms of mania or hypomania or any psychiatric admission before. In the first mental status examination, the Young Mania Rating Scale (YMRS) score was 33. On the twenty-eighth day of the hospitalization, the patient was discharged with the treatment of olanzapine 20 mg/day and clonazepam 0.5 mg/day since her YMRS score improved to 14. In spite of the fact that the core components of varenicline associated mania stay subtle, the present case report features the significance of monitoring for potential adverse reactions with the use of varenicline in patients with a history of depression, particularly when utilized in combination with antidepressants.

Key Words: Mania, psychotic features, smoking cessation, varenicline

(Ottukan J Clinical Psychiatry 2020;23:239-243)
DOI: 10.5505/kpd.2020.61214

ÖZET

Vareniklin dopaminergic etkileri de olan bir alfa 4 beta 2 nikotinik reseptör parsiyel agonistidir. Sigara bırakma tedavisinde onaylanmış etkili ve yaygın şekilde kullanılan bir ajandır. Vareniklin kullanım sırasında depresif duygudurum, uyku bozukluğu, intihar, ajitasyon, saldırganlık ve psikotik ve manik belirtiler bildirilmiştir. Bu olgu sunumunda 12haftalık vareniklin tedavisinin ardından psikotik özellikli mani tanısıyla hastaneyi yatıran ve depresyon öyküsü olan 48 yaşındaki bir kadın hastası sunuyoruz. Hasta dini grandiyez ve referans sanımları, işitsel ve görsel halüsinasyonlar, irritabilite, uykusuzluk ve hızlı konuşma belirtilerile psikiyatri kliniğiine kabul edildi. 2 yıldır sertralin 100 mg/gün tedavisi altında ve son 18 aydır ötümktü. Daha önce hiç mani/hipomani belirtisi ya da psikotik yatz öyküsü yoktu. İlk ruhsal durum muayenesinde Young Mania Derecelendirme Ölçeği (YMDO) 33 puan olarak değerlendirildiği hastada, yaşının 28. 20 mg/gün olanzapin 0.5 mg/gün değerlendirilmesi taburcu edildiğinde YMDO puanı 14 olarak değerlendirildi. Vareniklin ile ilişkili maninin merkezi mekanizmaları halen tam anlaşılmamış olsa da, olgumuz depresyon öyküsü olan hastalarda özellikle antidepressanlarla birlikte kullanıldığında vareniklinin potansiyel yan etkilerinin dikkatle izlenmesinin önemini vurgulamaktadır.

Anahtar Sözcükler: Mani, psikotik özellikleri, sigara bırakma, vareniklin
INTRODUCTION

Nicotine dependence is one of the most important public health problems because of the morbidity and mortality associated with smoking. Also, it is known that nicotine dependence rates are extremely high in patients with mental illness (1). Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist, approved by Food and Drug Administration (FDA) in 2006 for smoking cessation. Although it is not as potent as nicotine, it allows the release of dopamine from the nucleus accumbens so that dopamine is released in a continuous medium dose (2). By its antagonist effects, even if you take nicotine while using varenicline, there will not be an increase in dopamine release. It has shown efficacy over placebo and bupropion in manufacturer-sponsored trials (2).

There have been many case reports about psychiatric adverse effects associated with varenicline since its approval for the market (FDA alert, 2008). Following these findings, the FDA feel the necessity for a new black box warning, headlining the risk of developing psychiatric symptoms for Varenicline in July 2009 (3).

In spite of the existence of post-marketing concerns for neuropsychiatric adverse events, no significant increase in these events with varenicline compared to placebo was observed following randomized controlled trials, systematic reviews and meta-analyses of pharmacological interventions for smoking cessation (4,5,6,7,8,9,10,11,12)

There have been also several studies involving people with mental illness; however, no meaningfully increased risk of neuropsychiatric adverse events and/or exacerbation of mental illness during treatment with varenicline was found in these studies (13,14,15,16,17). Yet, those studies are open to criticism because of being open-label, uncontrolled, and/or underpowered, rendering them inadequate to determine the risk of neuropsychiatric adverse events (18).

Varenicline has been reported to induce hypomanic/manic episodes in patients with a pre-existing bipolar disorder (19,20,21) and mixed mood and psychotic episodes or mania in patients with a history of depression in recent studies (22,23,24). Besides, the reports of mania in patients who had no previous history of psychiatric disease during varenicline use have also been made (25,26,27,28).

Many problems arise in ascribing mania with the effects of medication. A great number of reports involve individual cases (29). Mania may occur by chance association during drug treatment, especially in patients prone to mood disorder (29). Thus, it is very likely that some patients will become manic during coincidental drug treatment (29). If the manic symptoms abate following the discontinuation of the drug and recur on rechallenge, establishing drug treatment as a causative agent in the individual patient is plausible; however, there is hardly any such information (29). Anti-parkinsonian drugs, corticosteroids, anabolic-androgenic steroids, antidepressants, antipsychotics, and many other drugs have been reported to be associated with manic symptoms.

Therefore, manias secondary to drugs are widely considered to be adverse drug events rather than indicators of a bipolarity; secondary manias typically resolve after drug cessation with time-limited symptomatic management as needed (30,31). The reflection of this perspective is noticed in DSM-IV, which classifies antidepressant-induced manias not as a subtype of bipolar illness, but as a substance-induced mood disorder (32). Conversely, DSM-5 indicates that hypomanic/manic episodes that occur during antidepressant treatment are, in certain circumstances, acknowledged as criteria for bipolar disorder (33). As a result, depressed patients developing mania or hypomania during antidepressant treatment, who are diagnosed with “substance-induced disorder” according to DSM IV-TR criteria, can be diagnosed as bipolar I or II according to DSM-5 criteria (33,34).

In this case report, we present a 48-year-old female patient with a history of depression and a new-onset manic episode after the discontinuation of varenicline treatment.

CASE

A 48-year-old married woman with a history of major depression was admitted to the psychiatry
Manic episode associated with Varenicline treatment in a patient with a history of depression

The patient does not have any significant physical health problems or any ongoing major psychosocial stressors. She does not have a history of alcohol or drug use. She has been a smoker of 20 cigarettes per day since the age of 25 years. In January 2010, she wanted to stop smoking and was prescribed varenicline by her doctor. The dose was titrated to 1-mg BID by day 8 and continued up to 12 weeks. On day 14, she stopped smoking with no withdrawal symptoms. She had no mood or behaviour changes during the 12-week treatment period. At the end of 12 weeks, she stopped varenicline and 2 days after discontinuation the patient developed restlessness, insomnia, irritability and acted strangely to her husband. The treatment protocol was presented in Figure 1.

Her husband also reported that she was more talkative than usual and became irritable and easily got nervous. She displayed reference ideas like believing that the things she saw in daily life had “special meaning” to her. She stopped her sertraline treatment because she thought that she had already recovered so she didn’t need drugs anymore and she was believing that she was a “healer”. She was thinking that she was given some special missions by God, one of which was to smoke cigarettes from now on, which may also be interpreted as the patient’s nicotine craving. Since then she had started to smoke 40 cigarettes/day, which was two times more than before commencing varenicline therapy.

She was taken to the emergency clinic by her husband since her symptoms worsened. On the first mental status examination in the emergency unit, her affect was labile and her mood was elevated and irritable. She had mystic grandiose delusions and auditory and visual hallucinations. She showed the pressure of speech. Her insight was impaired and her judgment was poor. She was admitted to the psychiatry clinic with a diagnosis of mania with psychotic features. On admission, she was delusional and agitated. Her vital signs were stable and her physical examination including neurological examination was normal. No abnormalities were observed in complete blood count, renal function tests, liver function tests, blood glucose, serum electrolytes, thyroid function tests, serum B12 vitamin and folic acid levels. Normal sinus rhythm with QTc 318 ms was seen in an electrocardiogram and no acute intracranial pathology was seen in a cranial CT scan. Young Mania Rating Scale (YMRS) score was 33. She was administered 10 mg/day olanzapine and 2 mg/day clonazepam. At the end of 4 weeks, YMRS score decreased to 14, her manic symptoms improved significantly but she wasn’t

Figure 1: Timeline of the patient’s varenicline dosage changes, smoking status and course of manic symptoms
Three months post discharge, the patient continued to be free of manic symptoms with compliance with her treatment. However, she showed mild depressive symptoms as partial anhedonia, low mood, fatigue and lack of energy. Her YMRS score was 0 and Montgomery–Åsberg Depression Rating Scale (MADRS) score was 8. In this visit, lamotrigine 25 mg was given to the patient. During follow-up, lamotrigine was gradually increased to 200 mg/day and olanzapine was gradually reduced to 5 mg/day due to sedation side effect. She has remained euthymic with this treatment for the last six years. At the time of writing, the patient was still at follow-up visits and euthymic with the treatment of lamotrigine 200 mg/day and olanzapine 5 mg/day.

**DISCUSSION**

Varenicline behaves like nicotine and provides a continuous medium-dose dopamine release in the mesolimbic system that may change the equation in the cholinergic-adrenergic tone. It is believed to be engaged in the pathophysiology of mania (35). Also, it was hypothesized that the nicotinic acetylcholine receptor may have mood-elevating effects (35). Potent α7 activation and weak α4β2 activation induced by varenicline may cause a central inhibitory dysfunction, which, accordingly, may result in manic symptoms in patients with bipolarity (23). Increasing dopaminergic activity in the central nervous system could also be accounted for the potential for psychotic symptoms (25,26,27,28).

There are several case reports of mania induced by initiating varenicline treatment in patients with or without a history of psychiatric illness (18,19,20) (23,24,25,26,27) (36,37) along with reported cases of psychosis about the varenicline withdrawal (38,39,40). In those reports, authors suggested that psychosis may have occurred because of the down-regulation of the cholinergic system resulted from an abrupt lack of cholinergic stimulation, which induced an anticholinergic response in individuals with genetic vulnerability (37,38,39). Our case differed from those with the absence of abrupt quit of varenicline during the 12-week treatment period. Our patient used varenicline in compliance with her physician’s prescription and discontinued following the recommended smoking cessation protocol. She had no mood or behaviour changes during 12-week treatment period. Given all these things, it does not seem possible that an abrupt lack of cholinergic stimulation-induced mania in our case.

Baker et al. (2016) reported a case of mania with psychotic features subsequent to the exposure to varenicline 3 weeks before self-ceasing the medication (28). The report states that the week following the cessation of varenicline the patient’s mental state began to deteriorate and continued to worsen gradually. This case report is claimed to show that it is possible that the withdrawal of varenicline might be associated with mental state disturbances in patients with no pre-existing mental disorder; however, the evidence base is limited.

It is possible that our patient’s manic episode was not causally associated with the cessation of varenicline. But it seems likely that indirect dopamine-releasing properties of varenicline may have contributed to the emergence of mania, also antidepressant-like properties may have potentiated the effect of sertraline in a patient with genetic vulnerability and positive family history and a manic shift occurred. The fact that there was no other manic or depressive episode under treatment during the next 6-year follow-up of the patient may also support that a patient in the bipolar spectrum may have developed a mania with psychotic features associated with varenicline.

In conclusion, further research is needed to deepen the data about the safety of varenicline, particularly among smokers with active or previous psychiatric history and with positive family history for psychiatric illness. Meanwhile, physicians should carefully monitor their patients throughout the use of varenicline in concern with mental status in compliance with FDA advice.

*Part of the data was presented at 23rd European Congress of Psychiatry (EPA 2015), Vienna, Austria, 28-31 March 2015

Correspondence address: M. D. Pınar Kızılay Çankaya, Ankara Training and Research Hospital, Psychiatry Clinic, Ankara, Turkey pkizilay@gmail.com
REFERENCES


